Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback

on MSN ago, source:

Verve Therapeutics shares dropped more than 30% early Tuesday after the company paused enrollment in a trial of its ...

Verve Therapeutics Inc (VERV) Shares Plummet Below 1-Year High

1d ago, source: newsheater

Based on Verve Therapeutics Inc (VERV), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -2.0. The debt to equity ratio ...

Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol

17d ago, source: Hosted on MSN

Verve and Beam Therapeutics Inc (NASDAQ:BEAM) entered into a collaboration and license agreement in April 2019, under which Verve received exclusive access to Beam’s base editing, gene editing ...

Verve Therapeutics Inc VERV

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After a Serious Setback, Is Verve Therapeutics a Buy?

on MSN ago, source:

This setback won't sink the company. In fact, it's actually a buying opportunity, assuming you're risk tolerant enough to invest in a pre-revenue biotech stock. It's entirely possible that VERVE-102 ...

Buy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recovery

11d ago, source:

Verve Therapeutics (VERV) has received a new Buy rating, initiated by H.C. Wainwright analyst, Mitchell Kapoor. Mitchell Kapoor has given his ...

Verve Therapeutics Inc (VERV) Stock: Evaluating the Market Performance

9d ago, source: newsheater

Smart investors will not be hesitating on this one! Verve Therapeutics Inc (NASDAQ: VERV)’s stock price has dropped by -7.20 in relation to previous closing price of 8.75. Nevertheless, the company ...

Commit To Purchase Verve Therapeutics At $10, Earn 22.4% Annualized Using Options

28d ago, source: Nasdaq

Investors eyeing a purchase of Verve Therapeutics Inc (Symbol: VERV) shares, but tentative about paying the going market price of $13.11/share, might benefit from considering selling puts among ...

Buy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recovery

11d ago, source: Business Insider

Verve Therapeutics (VERV) Company Description: Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management ...

Verve Therapeutics Inc (VERV)

17d ago, source: Investing

On Wednesday, BMO Capital Markets adjusted its price target on Verve Therapeutics (NASDAQ:VERV) shares. The firm reduced the price target to $30 from the previous $56, while ...